Nuclera secures £57m Series C funding led by Elevage Medical Technologies to scale commercial operations
The Series C financing was led by Elevage Medical Technologies with backing from Patient Square Capital and other investors.
Nuclera is a biotechnology company that accelerates drug discovery through its benchtop eProtein Discovery system. The firm provides rapid, easy access to functional proteins to streamline laboratory workflows.
Nuclera has secured £57m in a Series C financing round led by Elevage Medical Technologies. The raise also saw participation from Patient Square Capital, British Patient Capital, Cambridge Innovation Capital, and several other backers, including Jonathan Milner and M&G Catalyst.
The capital will be deployed to drive the commercial expansion of the company's eProtein Discovery benchtop platform, particularly across markets in the United States and Europe. The system aims to simplify protein expression and purification for researchers by automating workflows and reducing processing times.
Elevage Medical Technologies led the transaction alongside backer Patient Square Capital. The funding follows growing adoption of the platform among academic institutions and commercial research organisations.
From the founder
"This significant investment demonstrates continued confidence in our team, our eProtein Discovery system, and our potential to revolutionize the way proteins are made. This funding will accelerate our mission to provide ready-to-use benchtop protein screening and making tools to empower protein scientists around the world. We are excited to enhance our support for our customers, enabling them to make proteins for drug discovery more efficiently and effectively for many years to come."
Michael Chen
CEO at Nuclera
Investor perspective
"Nuclera has developed a solution for one of the leading obstacles in drug discovery: access to proteins that are needed throughout the drug discovery process. The demand for Nuclera’s technology is expanding rapidly, as AI and structural biology continues to drive the pace of new discoveries in life sciences and drug development. Elevage is proud to support Nuclera and its leadership team as it continues to bring the eProtein Discovery System to drug discovery researchers across the globe to address their need for bespoke, rapid and convenient delivery of quality proteins."
Michael Wasserman
Chief Operating Officer, Elevage Medical Technologies
Use of funds
- 01Expand into international markets
Investors
Michael Wasserman
Elevage Medical Technologies
Patient Square Capital
British Patient Capital
Cambridge Innovation Capital
Jonathan Milner
GK Goh
M&G Catalyst
E Ink Holdings
Michael D. McCreary
Uni Power Group
Verve Ventures
